F-18-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
Annie Wong, Jason Callahan, Marleen Keyaerts, Bart Neyns, Johanna Mangana, Susanne Aberle, Alan Herschtal, Sonia Fullerton, Donna Milne, Amir Iravani, Grant A McArthur, Rodney J Hicks
CANCER IMAGING | BMC | Published : 2020
Background Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma. Biomarkers are urgently needed as a majority of patients do not respond, despite treatment-related toxicities. We analysed pre-treatment 18F-fluorodeoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) parameters to assess its correlation with patient outcome. Methods This retrospective study evaluated pre-treatment FDG PET/CT scans in a discovery cohort of patients with advanced melanoma treated with ipilimumab or anti-PD1. Pre-treatment scans were assessed for maximum tumoral standardised uptake value (SUVmax), metab..View full abstract
Related Projects (1)
AW received research support from the Royal Australasian College of Physicians.